"The United States Code is the official codification of the general and permanent laws of the United States of America. The Code was first published in 1926, and a new edition of the code has been published every six years since 1934. The 2012 edition of the Code incorporates laws enacted through the One Hundred Twelfth Congress, Second Session, the last of which was signed by the President on January 15, 2013. It does not include laws of the One Hundred Thirteenth Congress, First Session, enacted between January 2, 2013, the date it convened, and January 15, 2013. By statutory authority this edition may be cited "U.S.C. 2012 ed." As adopted in 1926, the Code established prima facie the general and permanent laws of the United States. The underlying statutes reprinted in the Code remained in effect and controlled over the Code in case of any discrepancy. In 1947, Congress began enacting individual titles of the Code into positive law. When a title is enacted into positive law, the underlying statutes are repealed and the title then becomes legal evidence of the law. Currently, 26 of the 51 titles in the Code have been so enacted. These are identified in the table of titles near the beginning of each volume. The Law Revision Counsel of the House of Representatives continues to prepare legislation pursuant to 2 U.S.C. 285b to enact the remainder of the Code, on a title-by-title basis, into positive law. The 2012 edition of the Code was prepared and published under the supervision of Ralph V. Seep, Law Revision Counsel. Grateful acknowledgment is made of the contributions by all who helped in this work, particularly the staffs of the Office of the Law Revision Counsel and the Government Printing Office"--Preface.

Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.

HIPAA privacy in the pharmacy / Brian A. Gallagher -- Medicare and Medicaid / Susan C. Winckler -- Certification in pharmacy : advanced level credentials, including specialty certification / Richard J. Bertin -- Collaborative drug therapy management / Marla J. Campbell -- Supportive personnel in pharmacy practice / Thomas George -- Quality improvement initiatives for pharmaceutical care / Garry Carneal -- Electronic prescribing / F. Nicholas Willard -- Telepharmacy : identifying legal issues for pharmacists / Edward D. Rickert, Melissa A. Madigan -- Medication error reporting / Jennifer Devine -- VIPPS : creating a new regulatory model for the Internet age / Carmen A. Catizone, Moira Gibbons.

A New York Times Bestseller Winner of the Chicago Tribune Heartland Prize Winner of the Hillman Prize for Book Journalism Named a best book of the year by: the Los Angeles Times the San Francisco Chronicle the Saint Louis Post-Dispatch the Chicago Tribune the Seattle Times "A stunning look at a problem that has dire consequences for our country.”-New York Post The dramatic story of Methamphetamine as it comes to the American Heartland-a timely, moving, account of one community's attempt to confront the epidemic and see their way to a brighter future. Crystal methamphetamine is widely considered to be the most dangerous drug in the world, and nowhere is that more true than in the small towns of the American heartland. Methland is the story of the drug as it infiltrates the community of Oelwein, Iowa (pop. 6,159), a once-thriving farming and railroad community. Tracing the connections between the lives touched by meth and the global forces that have set the stage for the epidemic, Methland offers a vital and unique perspective on a pressing contemporary tragedy. Oelwein, Iowa is like thousand of other small towns across the county. It has been left in the dust by the consolidation of the agricultural industry, a depressed local economy and an out-migration of people. If this wasn't enough to deal with, an incredibly cheap, long-lasting, and highly addictive drug has come to town, touching virtually everyone's lives. Journalist Nick Reding reported this story over a period of four years, and he brings us into the heart of the town through an ensemble cast of intimately drawn characters, including: Clay Hallburg, the town doctor, who fights meth even as he struggles with his own alcoholism; Nathan Lein, the town prosecutor, whose case load is filled almost exclusively with meth-related crime, and Jeff Rohrick, who is still trying to kick a meth habit after four years. Methland is a portrait of a community under siege, of the lives the drug has devastated, and of the heroes who continue to fight the war. It will appeal to readers of David Sheff's bestselling Beautiful Boy, and serve as inspiration for those who believe in the power of everyday people to change their world for the better.

This report highlights certain non-criminal regulatory requirements of the Controlled Substances Act (CSA). The CSA and its implementing regulations establish a framework through which the federal government regulates the use of controlled substances for legitimate medical, scientific, research, and industrial purposes, and prevents these substances from being diverted for illegal purposes. The CSA assigns various plants, drugs, and chemicals (such as narcotics, stimulants, depressants, hallucinogens, and anabolic steroids) to one of five schedules based on the substance's medical use, potential for abuse, and safety or dependence liability. Schedule I contains substances that have no currently accepted medical use and cannot safely be made available to the public under a prescription, while Schedules II, III, IV, and V include substances that have recognized medical uses and may be manufactured, distributed, and used in accordance with the CSA. The order of the schedules reflects substances that are progressively less dangerous and addictive. To restrict access to chemicals used in the illicit manufacture of certain controlled substances, the CSA also regulates 40 “listed chemicals.†Furthermore, the CSA regulates controlled substance “analogues,†which are substances that are not controlled but are structurally or pharmacologically similar to substances found in Schedule I or II and have no accepted medical use. This is a print on demand report.